Loading…
Quest Diagnostics Incorporated is projected to rise to $326.95 by 2027, a +39% move from its current price of $235.94. DGX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/29/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 31 | $232.65 | $236.04 | $239.48 | +0.04% |
| Aug 1 | $231.36 | $236.14 | $241.02 | +0.08% |
| Aug 2 | $230.40 | $236.24 | $242.23 | +0.13% |
| Aug 3 | $229.60 | $236.34 | $243.27 | +0.17% |
| Aug 4 | $228.92 | $236.44 | $244.20 | +0.21% |
| Aug 5 | $228.31 | $236.54 | $245.06 | +0.25% |
| Aug 6 | $227.76 | $236.64 | $245.86 | +0.29% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $227.76 | $236.64 | $245.86 | +0.29% |
| Week 2 | $224.84 | $237.33 | $250.52 | +0.59% |
| Week 3 | $222.78 | $238.03 | $254.34 | +0.89% |
| Week 4 | $221.16 | $238.74 | $257.71 | +1.19% |
| Week 5 | $219.81 | $239.44 | $260.82 | +1.48% |
| Week 6 | $218.67 | $240.15 | $263.73 | +1.78% |
| Week 7 | $217.67 | $240.85 | $266.50 | +2.08% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Quest Diagnostics Incorporated (DGX) is a healthcare company that provides diagnostic testing and diagnostic information services in the United States. It offers routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services under the Quest Diagnostics brand as well as AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile teams, nurses and other health and wellness professionals. The company also delivers population health solutions, risk assessment services for the life insurance industry, and testing across cardiometabolic and endocrine, cancer, clinical drug monitoring, infectious disease, neurology, and women’s health, among others.
Quest Diagnostics was founded in 1967 and is headquartered in Secaucus, New Jersey.
DGX is a healthcare stock focused on diagnostic testing and related information services in the United States. It currently trades at $227.90 per share and carries a market capitalization of $25.07B, with a rank of 506. The long-run forecast shows meaningful upside, with the 2026 average price at $227.90 and the 2030 average price at $468.39, rising further to $2,423.25 on average by 2050, and a max forecast of $3,961.42 in 2050.
In the near term, the outlook begins neutral in 2026 before a bullish trajectory unfolds in subsequent years. Near-term technicals place DGX in a bullish context while the stock navigates a range defined by support at $193.58 and resistance at $227.90, with a 30-day trading range from $206.39 to $251.65.
A major floor 23.9% below — a decisive break under it would weaken the trend.
The nearest floor, 18.0% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 12.0% above — clearing it would confirm fresh momentum.
Key DGX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DGX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $226.67 | Buy | $227.59 | Buy |
| MA 10 | $216.97 | Buy | $221.10 | Buy |
| MA 20 | $213.82 | Buy | $215.11 | Buy |
| MA 50 | $204.21 | Buy | $207.30 | Buy |
| MA 100 | $199.96 | Buy | $201.63 | Buy |
| MA 200 | $193.27 | Buy | $194.53 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 76.71 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 203.76 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 2.57 | Buy |
| ROC (12) | 13.74 | Buy |
| Bollinger %B (20,2) | 1.10 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.28 | Buy |
| Awesome (5,34) | 17.55 | Buy |
| Ultimate (7,14,28) | 82.90 | Sell |
| Momentum (10) | 29.94 | Buy |
| Aroon Osc (25) | 100.00 | Buy |
| Hull MA (9) | 237.09 | Sell |
| ADX (14) | 23.78 | Buy |
| ATR (14) | 3.37 | Info |
The 30-day technical picture is bullish. RSI(14) is 70, indicating strong momentum, and the price is above the 50-day simple moving average of $201.67 and the 200-day simple moving average of $192.50. The stock is trading between a support level of $193.58 and a resistance at $227.90.
Over the next 30 days, the price has traced a range from $206.39 to $251.65, reflecting constructive volatility and upside potential.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $173.49 | $235.94 | $311.99 | 0% | Neutral | |
| $268.05 | $326.95 | $416.76 | +39% | Bullish | |
| $304.02 | $377.88 | $494.88 | +60% | Bullish | |
| $354.40 | $447.35 | $598.45 | +90% | Bullish | |
| $397.75 | $508.89 | $693.14 | +116% | Bullish | |
| $406.57 | $526.55 | $728.59 | +123% | Bullish | |
| $453.50 | $593.99 | $833.65 | +152% | Bullish | |
| $496.91 | $657.72 | $935.09 | +179% | Bullish | |
| $578.18 | $772.93 | $1,112.06 | +228% | Bullish | |
| $693.99 | $936.54 | $1,362.52 | +297% | Bullish | |
| $906.18 | $1,275.57 | $1,944.95 | +441% | Bullish | |
| $1,868.24 | $2,820.61 | $4,610.64 | +11.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $173.49 | $235.94 | $275.40 | +0.00% |
| August 2026 | $204.80 | $238.91 | $284.11 | +1.26% |
| September 2026 | $208.99 | $245.17 | $294.23 | +2.62% |
| October 2026 | $207.55 | $244.58 | $295.67 | -0.24% |
| November 2026 | $207.65 | $245.61 | $298.69 | +0.42% |
| December 2026 | $214.99 | $255.16 | $311.99 | +3.89% |
Click any year to see its month-by-month DGX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The DGX price prediction for 2026 points to an average of $235.94 (low $173.49, high $311.99) — a potential gain of 0% on today's $235.94. Price action looks broadly range-bound.
In 2027, DGX is projected to trade between $268.05 and $416.76, averaging $326.95 — a potential gain of +39% from today's $235.94. That is up +39% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Quest Diagnostics Incorporated's 2028 outlook centres on $377.88, within a $304.02 to $494.88 range. That is up +16% on the projected 2027 average. That marks a +60% change versus current levels. Momentum favours further upside here.
By 2029, DGX could reach as high as $598.45, with a base case around $447.35 and support toward $354.40 — roughly +90% from $235.94. Buyers look set to stay in control over this stretch.
Expect DGX to range from $397.75 to $693.14 through 2030. The $508.89 average target implies a +116% move from current prices. That is up +14% on the projected 2029 average. Momentum favours further upside here.
The DGX price prediction for 2031 points to an average of $526.55 (low $406.57, high $728.59) — a potential gain of +123% on today's $235.94. Buyers look set to stay in control over this stretch.
In 2032, DGX is projected to trade between $453.50 and $833.65, averaging $593.99 — a potential gain of +152% from today's $235.94. That is up +13% on the projected 2031 average. Momentum favours further upside here.
Quest Diagnostics Incorporated's 2033 outlook centres on $657.72, within a $496.91 to $935.09 range. That is up +11% on the projected 2032 average. That marks a +179% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, DGX could reach as high as $1,112.06, with a base case around $772.93 and support toward $578.18 — roughly +228% from $235.94. Momentum favours further upside here.
Expect DGX to range from $693.99 to $1,362.52 through 2035. The $936.54 average target implies a +297% move from current prices. That is up +21% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The DGX price prediction for 2040 points to an average of $1,275.57 (low $906.18, high $1,944.95) — a potential gain of +441% on today's $235.94. Momentum favours further upside here.
In 2050, DGX is projected to trade between $1,868.24 and $4,610.64, averaging $2,820.61 — a potential gain of +11.0x from today's $235.94. That is up +121% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in DGX today (≈ 4.238366 DGX) could be worth
$11,954.79
+$10,954.79 (+1095%) by 2050 · US Dollar
Based on the average projected DGX price of $2,820.61 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DGXwould be worth at today's price.
$1,000 invested in DGX on Jul 28, 2025 (≈ 5.9577 DGX) would be worth
$1,405.66
+$405.66 (+40.6%) today · 1.41× · US Dollar
Based on a DGX entry price of $167.85 vs. today's $235.94.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $206.84 | $1,140.69 | +14.1% |
| 1 month ago | $212.64 | $1,109.57 | +11.0% |
| 3 months ago | $189.32 | $1,246.25 | +24.6% |
| 6 months ago | $182.35 | $1,293.89 | +29.4% |
| 1 year ago | $167.85 | $1,405.66 | +40.6% |
| All time (5.0y) ago | $143.04 | $1,649.47 | +64.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DGX forecast.
Our base-case forecast reaches $470.00 around 2030.
Implied market cap at $470.00: $51.88B
The multi-year forecast shows substantial upside from 2027 onward, with an average price rising from $308.31 in 2027 to $468.39 in 2030 and continuing higher to $2,423.25 by 2050. The model also indicates very large maximums, with $3,961.42 by 2050, and strong bullish sentiment through 2031–2050. The implied returns rise from 0% in 2026 to 105.5% by 2030 and accelerate to 386.8% by 2040 and 963.3% by 2050.
These are estimates of potential price paths and are not guaranteed. Investors should consider the long-run upside alongside the near-term neutral start in 2026 and the inherent uncertainties in any forecast.
Tap a question to reveal the answer.
2030 forecast: avg $468.39, min $366.03, max $638.12; ROI 105.5%; sentiment BULLISH.
The 2026 forecast is neutral with avg price $227.90 and ROI 0%, but the outlook from 2027 onward is BULLISH with meaningful upside through 2050; these are estimates and not guarantees.
Yes—the forecast max reaches $1,691.79 by 2040 and $3,961.42 by 2050, indicating a path well above $1,000 sometime in the forecast horizon.
Current price is $227.90; market capitalization is $25.07B.
The 30-day range is $206.39 to $251.65. RSI(14) is 70. SMA50 is $201.67 and SMA200 is $192.50. Support is at $193.58 and resistance at $227.90.
Quest Diagnostics Incorporated Community Discussion
0Share your Quest Diagnostics Incorporated price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.